metricas
covid
Buscar en
Actas Urológicas Españolas (English Edition)
Toda la web
Inicio Actas Urológicas Españolas (English Edition) Expression of PD-L1 in renal cancer, prognostic features and clinical utility of...
Journal Information
Vol. 47. Issue 5.
Pages 271-278 (June 2023)
Share
Share
Download PDF
More article options
Vol. 47. Issue 5.
Pages 271-278 (June 2023)
Original article
Expression of PD-L1 in renal cancer, prognostic features and clinical utility of its routine staining
Expresión de PD-L1 en cáncer renal, características pronósticas y utilidad en la práctica clínica habitual
R. Massouh Skorina,
Corresponding author
rnmassou@uc.cl

Corresponding author.
, P. Escovar la Rivaa, F. Gablerb, M. Kirmayrc, T. Khamisd, S. Escobarc, A. Díazb, L. Sotob
a Department of Urology, Hospital Clínico San Borja Arriarán, Santiago, Chile
b Department of Pathology, Hospital Clínico San Borja Arriarán, Santiago, Chile
c Department of Urology, Hospital del Salvador, Santiago, Chile
d Univeristy of Chile, Santiago, Chile
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (2)
Tables (1)
Table 1. Patients characteristics.
Abstract
Introduction

The expression of PD-L1 in renal cell carcinoma (RCC) is associated with worse survival and prognostic clinical-pathological features. However, they seem to respond better to new therapeutic agents. Knowing the behavior of RCC according to the presence of PD-L1 has implications for medical counseling and therapeutic approaches.

Objective

To identify the presence of PD-L1 in renal tumor cells and analyze its association with patients’ prognostic factors, overall survival (OS) and cancer-specific survival (CSS).

Methodology

Retrospective analysis of RCC tissue samples, obtained between 2018 and 2021. Immunohistochemistry analysis with mouse monoclonal Anti PD-L1, clone 22C3. Definition of PD-L1 “positive” as a Tumor Proportion Score ≥1%. Comparison of prognostic factors according to the presence or absence of PD-L1, and univariate analysis for OS and CSS.

Results

14% (n = 11) of the sample were PD-L1(+). Average age was 59 years. There were no statistically significant differences between PD-L1 status and TNM stages, nuclear grade and histology. PD-L1(+) had worse OS with a HR of 5.27 (CI: 1.1–23.7; P = .03) and CSS showed a unfavorable tendency for PD-L1(+) with a HR of 4.79 (CI: 0.79–28.95; P = .08).

Conclusion

The prevalence of PD-L1 in RCC is considerable. In this study PD-L1(+) was associated with unfavorable OS and CSS. It seems reasonable to incorporate its routine use in RCC.

Keywords:
Renal cell carcinoma
PD-L1
Overall survival
Prognostic
Abbreviations:
RCC
OS
Resumen
Introducción

La expresión de PD-L1 en el carcinoma de células renales (CCR) se asocia a tasas de supervivencia y características clínico-patológicas pronósticas peores. Sin embargo, estas parecen responder mejor ante nuevos agentes terapéuticos. Conocer el comportamiento del CCR según la presencia de PD-L1 tiene implicaciones sobre el asesoramiento de los pacientes y el abordaje terapéutico.

Objetivo

Identificar la presencia de PD-L1 en las células tumorales renales y analizar su asociación con los factores pronósticos de los pacientes, la supervivencia global (SG) y la supervivencia cáncer-específica (SCE).

Metodología

Análisis retrospectivo a partir de muestras de tejido de CCR obtenidas entre 2018 y 2021. Estudio inmunohistoquímico con monoclonal de ratón anti PD-L1, clon 22C3. Se definió PD-L1 “positivo” como una puntuación de proporción tumoral ≥1%. Comparación de factores pronósticos según la presencia o ausencia de PD-L1, y análisis univariante para la SG y la SCE.

Resultados

Un 14% (n = 11) de la muestra era PD-L1(+). La edad media era de 59 años. No hubo diferencias estadísticamente significativas entre el estatus de PD-L1 y el estadio TNM, el grado nuclear y el tipo histológico. Los pacientes PD-L1(+) tuvieron peor SG con un HR de 5,27 (IC: 1,1–23,7; P = ,03) y la SCE mostró una tendencia desfavorable para PD-L1(+) con un HR de 4,79 (IC: 0,79–28,95; P = ,08).

Conclusión

La prevalencia de PD-L1 en el CCR es considerable. En este estudio, PD-L1(+) se asoció con una SG y SCE desfavorables, lo que justifica incorporar su uso rutinario en el CCR.

Palabras clave:
Carcinoma de células renales
PD-L1
Supervivencia global
Pronóstico

Article

These are the options to access the full texts of the publication Actas Urológicas Españolas (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Actas Urológicas Españolas (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos